作者
Zahari Vinarov, Mohammad Abdallah, José AG Agundez, Karel Allegaert, Abdul W Basit, Marlies Braeckmans, Jens Ceulemans, Maura Corsetti, Brendan T Griffin, Michael Grimm, Daniel Keszthelyi, Mirko Koziolek, Christine M Madla, Christophe Matthys, Laura E McCoubrey, Amitava Mitra, Christos Reppas, Jef Stappaerts, Nele Steenackers, Natalie L Trevaskis, Tim Vanuytsel, Maria Vertzoni, Werner Weitschies, Clive Wilson, Patrick Augustijns
发表日期
2021/7/1
来源
European Journal of Pharmaceutical Sciences
卷号
162
页码范围
105812
出版商
Elsevier
简介
The absorption of oral drugs is frequently plagued by significant variability with potentially serious therapeutic consequences. The source of variability can be traced back to interindividual variability in physiology, differences in special populations (age- and disease-dependent), drug and formulation properties, or food-drug interactions. Clinical evidence for the impact of some of these factors on drug pharmacokinetic variability is mounting: e.g. gastric pH and emptying time, small intestinal fluid properties, differences in pediatrics and the elderly, and surgical changes in gastrointestinal anatomy. However, the link of colonic factors variability (transit time, fluid composition, microbiome), sex differences (male vs. female) and gut-related diseases (chronic constipation, anorexia and cachexia) to drug absorption variability has not been firmly established yet. At the same time, a way to decrease oral drug pharmacokinetic …
引用总数
学术搜索中的文章
Z Vinarov, M Abdallah, JAG Agundez, K Allegaert… - European Journal of Pharmaceutical Sciences, 2021